Michael A. Panzara M.D., M.P.H., MPH
Net Worth
Last updated:
What is Michael A. Panzara M.D., M.P.H., MPH net worth?
The estimated net worth of Dr. Michael A. Panzara M.D., M.P.H., MPH is at least $7,429,647 as of 5 May 2022. He owns shares worth $1,038,661 as insider, has earned $1,150,986 from insider trading and has received compensation worth at least $5,240,000 in Wave Life Sciences Ltd..
What is the salary of Michael A. Panzara M.D., M.P.H., MPH?
Dr. Michael A. Panzara M.D., M.P.H., MPH salary is $655,000 per year as Chief Medical Officer and Head of Therapeutics Discovery & Devel. in Wave Life Sciences Ltd..
How old is Michael A. Panzara M.D., M.P.H., MPH?
Dr. Michael A. Panzara M.D., M.P.H., MPH is 58 years old, born in 1967.
What stocks does Michael A. Panzara M.D., M.P.H., MPH currently own?
As insider, Dr. Michael A. Panzara M.D., M.P.H., MPH owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Wave Life Sciences Ltd. (WVE) | Chief Medical Officer and Head of Therapeutics Discovery & Devel. | 109,103 | $9.52 | $1,038,661 |
What does Wave Life Sciences Ltd. do?
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Michael A. Panzara M.D., M.P.H., MPH insider trading
Wave Life Sciences Ltd.
Dr. Michael A. Panzara M.D., M.P.H., MPH has made 10 insider trades between 2017-2022, according to the Form 4 filled with the SEC. Most recently he sold 16,714 units of WVE stock worth $28,748 on 5 May 2022.
The largest trade he's ever made was exercising 18,750 units of WVE stock on 15 Feb 2018. As of 5 May 2022 he still owns at least 109,103 units of WVE stock.
Wave Life Sciences Ltd. key executives
Wave Life Sciences Ltd. executives and other stock owners filed with the SEC:
- Dr. Chandra Vargeese Ph.D. (64) Chief Technology Officer
- Dr. Michael A. Panzara M.D., M.P.H., MPH (58) Chief Medical Officer and Head of Therapeutics Discovery & Devel.
- Dr. Paul B. Bolno M.B.A., M.D., MBA (51) Pres, Chief Executive Officer & Director